Early-stage healthcare companies are fraught with risk. In essence, they are companies that believe something could be a valuable product, but they still have to test it to make sure. It costs huge ...

Regencell Bioscience (NASDAQ: RGC), a China-based drugmaker, has been on fire over the past 12 months, with its share price skyrocketing by more than 21,000% as of this writing (that's not a typo). A ...

Regencell Bioscience remains severely overvalued at a $6 billion market cap, despite having no revenue, assets, or business activity. RGC's 20-F filing revealed three material weaknesses in internal ...

Regencell Bioscience Holdings Limited has surged 23,745% in 2025, reaching a $12b market cap despite having zero revenue. RGC's explosive upside is driven by float mechanics, with the founder and his ...

These ten large-cap stocks were the worst performers last week. Are they a part of your portfolio? Zscaler, Inc. ZS fell ...

Levi & Korsinsky, LLP encourages investors who suffered losses in Regencell Bioscience Holdings Limited (NASDAQ: RGC) to contact the firm. Those who purchased RGC securities between October 28, 2024 ...

View Regencell Bioscience Holdings Ltd. RGC stock quote prices, financial information, real-time forecasts, and company news from CNN.

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regencell Bioscience Holdings Limited (NASDAQ: RGC) between October 28, 2024 and October 31, 2025, inclusive ...

Detailed price information for Regencell Bioscience Holdings Ltd (RGC-Q) from The Globe and Mail including charting and trades.

Regencell Bioscience's investor website explains that it is an early-stage bioscience company working on TCM. It lists indications such as neurocognitive disorders and infectious diseases as areas of ...

Regencell Bioscience's outrageous performance in the past year is baffling. Despite the stock's sharp rise, there is little to look forward to for the drugmaker. Pfizer is a much better bet with its ...